Product Information
AMITRIPTYLINE HCL 50 MG TAB is a generic product labeled by Rising Pharma Holdings Inc., priced at $0.0963 per EA under NDC 16571010701. Its NADAC has been published 153 times since Nov 1, 2023.
FDA first approved this application on May 19, 2023. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
50 mg/1
Manufacturer
Rising Pharma Holdings Inc.NDC
16571010701
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
AMITRIPTYLINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA217411FDA Approved
5/19/2023
TE Code
AB
On Market Since
6/10/2023
Pharmacological Classes
Price Statistics
The NADAC for AMITRIPTYLINE HCL 50 MG TAB has been published 153 times since Nov 1, 2023, and over the history we have for it it has risen 5.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0963 per EA |
|---|---|
| All-time high | $0.1251 (Apr 10, 2024) |
| All-time low | $0.0677 (Nov 20, 2024) |
| 52-week high | $0.1019 |
| 52-week low | $0.0889 |
| Median price | $0.0920 |
| Average price | $0.0904 |
| Largest weekly change | +40.1% (Aug 21, 2024) |
| Weeks tracked | 153 |
| Tracking since | Nov 1, 2023 |
Generic Alternatives
The matcher finds 12 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rising Pharma Holdings Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Amitriptyline Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Tricyclic Antidepressant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of AMITRIPTYLINE HCL 50 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for AMITRIPTYLINE HCL 50 MG TAB, manufactured by Rising Pharma Holdings Inc., is $0.0963 per EA (NDC 16571010701), effective Sep 30, 2026.
How has the price of AMITRIPTYLINE HCL 50 MG TAB changed over time?
Over the history we have for it, the NADAC for AMITRIPTYLINE HCL 50 MG TAB has risen 5.7%. It has been tracked across 153 weekly CMS publications since Nov 1, 2023.
What are the highest and lowest recorded NADAC prices for AMITRIPTYLINE HCL 50 MG TAB?
Since Nov 1, 2023, the NADAC for AMITRIPTYLINE HCL 50 MG TAB has ranged from a low of $0.0677 (Nov 20, 2024) to a high of $0.1251 (Apr 10, 2024), with a median of $0.0920 per EA.
Are there cheaper alternatives to AMITRIPTYLINE HCL 50 MG TAB?
12 manufacturers publish a NADAC-priced product with the same active ingredient and strength as AMITRIPTYLINE HCL 50 MG TAB in a comparable dosage form, but none are currently priced below it.
Who manufactures AMITRIPTYLINE HCL 50 MG TAB?
AMITRIPTYLINE HCL 50 MG TAB (NDC 16571010701) is labeled by Rising Pharma Holdings Inc., and CMS classifies it as a generic product.